# Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency

> **NCT00743483** · PHASE2 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 15 (actual)

## Conditions studied

- Cystic Fibrosis
- Exocrine Pancreatic Insufficiency

## Interventions

- **DRUG:** rhBSSL

## Key facts

- **NCT ID:** NCT00743483
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743483, "Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00743483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*